Sharps Compliance Reports Fiscal 2017 Fourth Quarter Results
Aug 10, 2017 10:55 am UTC| Business
Fourth quarter revenue increased 17%;Professional market billings increased 57%;Pharmaceutical Manufacturer and Assisted Living billings increased 50% and 14%, respectively;Return to profitability with EPS of $0.04; andFlu...
Hill International Delays Filing of Second Quarter 2017 Financial Results and Conference Call
Aug 10, 2017 10:50 am UTC| Business
PHILADELPHIA, Aug. 10, 2017 -- Hill International (NYSE:HIL), the global leader in managing construction risk, announced today that it has delayed the release of its second quarter 2017 financial results, which was...
Aug 10, 2017 10:45 am UTC| Business
SAN FRANCISCO, Aug. 10, 2017 -- The Global Cleanroom Technology Market Report, published by Variant Market Research, forecast that the global market is expected to reach $5,171 million by 2024 from $3,474 million in...
Crown Crafts Reports Fiscal 2018 First Quarter Results
Aug 10, 2017 10:45 am UTC| Business
Positive net income reported in seasonally slowest quarterAddition of Carousel Designs and strong product offerings position Company for the futureCompany remains debt-free GONZALES, La., Aug. 10, 2017 -- Crown Crafts,...
Auris Medical Provides Business Update and Reports Second Quarter 2017 Financial Results
Aug 10, 2017 10:31 am UTC| Business
Phase 3 results from AM-111 HEALOS trial expected in fourth quarter 2017 Phase 3 results from Keyzilen® TACTT3 trial expected in first quarter 2018 Conference call set for 8 am EDT (2 pm CEST) today Zug,...
Superconductor Technologies Reports 2017 Second Quarter Results
Aug 10, 2017 10:30 am UTC| Business
AUSTIN, Texas, Aug. 10, 2017 -- Superconductor Technologies Inc. (STI) (Nasdaq:SCON) reported financial results for the quarter ended July 1, 2017. Jeff Quiram, STI’s president and CEO, stated, “In the second quarter,...
Histogenics Corporation Announces Second Quarter 2017 Financial and Operating Results
Aug 10, 2017 10:30 am UTC| Business
‒ Completed Enrollment in NeoCart® Phase 3 Clinical Trial ‒‒ Top-line Data and Potential BLA Filing Expected in Third Quarter of 2018 ‒‒ Defined Regulatory Pathway with Japan Pharmaceuticals and Medical Devices Agency ‒‒...